EVAUX® announces the presentation of the results of a clinical study at the 7th International Congress on Neuropathic Pain, held in London from 9 to 11 May 2019 (7th International Congress on Neuropathic Pain *) 2

EVAUX® announces the presentation of the results of a clinical study at the 7th International Congress on Neuropathic Pain, held in London from 9 to 11 May 2019 (7th International Congress on Neuropathic Pain *)

Posted in health

* https: //www.eventscribe.com/2019/NeuPSIG/aboutcongress.asp A forum that presents the latest research and advances in understanding, preventing and treating neuropathic pain.

A clinical study titled “Interest in Local Treatment for Painful Diabetic Neuropathy,” poster EP-124, demonstrates the value of local treatment for painful diabetic neuropathy.

Diabetic neuropathy includes a group of diabetes complications that can cause pain, numbness, numbness, or loss of sensation (pain, cold, etc.). Between 20% and 60% of people with diabetes (type 1 and type 2) have some form of neuropathy, which can be associated with legs, feet, hands, or arms. 650,000 people suffer from painful neuropathy in France **.

Managing diabetic neuropathy remains a problem. Topical treatment is of great interest due to the frequent side effects caused by oral treatment.

** Management of a diabetic foot in a specialized center K. Van Aker – B. Wandelin – F. Vermassin – T. Lemrieis: ed. Albe de Cocker 2008

ABOUT STUDY
The study, conducted by Professor Phillips of the University Hospital of Liege, on 22 patients (12 women / 10 men); Type 1 diabetes: 21.05%; Type 2 diabetes: 78.95%; Duration of LAP and FOOT: 2 times a day for 1 month.

The results of the EVAUX® study show, after one month of use of PIEDS & LEGS, a significant reduction in pain and, in particular, pain symptoms, as indicated in the DN4 questionnaire.

• burns
• painful cold
• electric shock
• tingling
• tingling
• numbness
• itching

In numbers
Symptoms of the DN4 questionnaire are reduced from 30% to 67%.
58% of patients report a reduction in pain at the end of the study (1 month).
47% of patients would like to continue using the product PIEDS & LEVES.

conclusion
The use of FEET & LEGS causes a decrease in pain in more than half of the patients, who praised the convenience and ease of use.

ABOUT PRODUCT LEGS AND LEGS
Product PIEDS & LEGS, gel cream, designed to care for lower limbs, is designed to maintain high-quality skin and soothe neuropathic genes.

PIEDS & LEVES is sold in pharmacies
Non-greasy cream gel
Pump bottle for presentations 250ml
ACL code 3760031691185 – CNK code 3782-661
Recommended retail price 19.80 €

The PIEDS & LEGS product is also the subject of a clinical study at the Fagnes Health Center (Chimay – Belgium), a branch of Dr. Christian Van Acker. "Evaluation of the effectiveness of cream-gel PIEDS & LEGS compared with Dexeryl® in primary prevention in patients with type 1 or type 2 diabetes: restoration of hydration." The preliminary results are very convincing.

About Us
EVAUX®, a French dermatological laboratory, is developing its experience in the field of dermo-cosmetic care based on the properties of hyperthermic water from Evaux les Bains, France. Numerous medical studies have confirmed the effectiveness of EVAUX® dermo-cosmetic products. EVAUX® products are freely available in pharmacies and other specialty stores. International markets are currently the goal of the laboratory.

WEBSITES
www.evauxlaboratoires.com
This email address is protected from spam bots. You must enable javascript to view it.


Press contact:

Evaux Laboratories

This email address is protected from spam bots. You must enable javascript to view it.
http://www.evauxlaboratoires.com


statement sent to 2019-05-10 12:08:15 through Categorynet.com website in the Health section

Broadcast your press release: http://www.diffuseruncommuniquedepresse.com

______